Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Belgium

- PMLiVE

Pfizer’s RSV vaccine granted EC approval to protect infants and older adults

The decision allows Abrysvo to be given to those who are 24 to 36 weeks into their pregnancy

- PMLiVE

Pfizer and Astellas’ Xtandi granted FDA priority review for new prostate cancer indication

The treatment is already approved in the US for three disease states of prostate cancer

- PMLiVE

Pfizer’s maternal RSV vaccine granted FDA approval to protect infants

The decision allows Abrysvo to be given to those who are 32 to 36 weeks into their pregnancy

- PMLiVE

GSK files lawsuit against Pfizer over RSV vaccine patent infringement

The RSV vaccine market is estimated to exceed $5bn and could surpass $10bn by 2030

- PMLiVE

AstraZeneca’s rare disease unit to acquire Pfizer’s early-stage gene therapies for $1bn

The transaction could potentially see staff associated with the portfolio move to Alexion

- PMLiVE

Health and Social Care Committee report on vaccination calls for urgent action in the UK

In England, coverage for childhood immunisations was below target in 2021 and 2022

- PMLiVE

Pfizer and Flagship Pioneering sign drug discovery partnership worth up to $7bn

The partners will each invest $50m upfront to develop up to ten new drug candidates

- PMLiVE

US FTC requests more information on Pfizer’s proposed $43bn Seagen acquisition

The transaction would mark a significant boost to Pfizer’s oncology pipeline

- PMLiVE

UK life sciences sector sees substantial drop in international investment

The estimated value of inward foreign direct investment fell from £1.9bn in 2021 to £1bn in 2022

- PMLiVE

Pfizer’s Litfulo approved by FDA as first treatment for adolescents with severe alopecia areata

Almost 20% of patients with the autoimmune disease are diagnosed before the age of 18

- PMLiVE

Pfizer’s Talzenna combination receives FDA approval for metastatic prostate cancer

Up to 20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

Pfizer reports positive results for elranatamab in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links